Cover
Vol. 11 No. 2 (2021)

Published: October 31, 2021

Pages: 1-14

Research Article

Effect of Administration of Single Dose GnRH Agonist in Luteal Phase on Implantation Rate of Fresh ICSI Cycles

Sally Alaa 1 Nadia Al-Hilli Mufeda Ali Jwad
1High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq.
History
  • Received: June 10, 2021
  • Accepted: October 3, 2021
  • Available Online: October 8, 2021
DOI

https://doi.org/10.28969/IJEIR.v11.i2.r1

Abstract

The luteal phase (LP) in the fresh ICSI cycle is insufficient, adequate LP support is one of the approved treatments for improving implantation and pregnancy rates. It is generally known that the LP is inadequate after ovarian stimulation due to negative from supra-physiological blood levels of steroids released by numerous corporal luteal, LH concentrations are low during the luteal phase. In this study, patients were divided into two groups: (40) patients as study group; those who received GnRHa (Decapeptil 0.1 mg), three days after embryo transfer, in addition to conventional luteal phase support (LPS) in the LP to increase the implantation and pregnancy rate in IVF; and their control group (40) received standard LPS only. On the second day of stimulation, blood samples for FSH, LH, TSH, E 2 , and prolactin were taken. On the day of ovulation induction, measure E 2 , progesterone, and LH; and on the day of embryo transfers, measure progesterone and LH. The overall characteristics of the patients in both groups were not significantly different. There was also no significant change in the number of total oocytes, mean of metaphase II oocytes percent, cleavage rate, grade I embryo percent, or serum hormones level between the study and control groups (p > 0.05). GnRH agonist treatment in the luteal phase improves clinical pregnancy and implantation rate in fresh ICSI cycles but is not statistically significant.

Keywords

References

  1. Moridi A, Roozbeh N, Yaghoobi H, Soltani S, Dashti S, Shahrahmani N, et al. Etiology and Risk Factors Associated With Infertility. International Journal of Women’s Health and Reproduction Sciences. International Journal of Women’s Health; 2019 Mar 10;7(3):346–53. [Online article link]
  2. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertility and Sterility. Elsevier BV; 2017 Sep;108(3):393–406. [Online article link]
  3. Nardelli AA, Stafinski T, Motan T, Klein K, Menon D. Assisted reproductive technologies (ARTs): Evaluation of evidence to support public policy development. Reproductive Health. Springer Science and Business Media LLC; 2014 Nov 7;11(1). [Online article link]
  4. Zhang S, Lin H, Kong S, Wang S, Wang H, Wang H, et al. Physiological and molecular determinants of embryo implantation. Molecular Aspects of Medicine. Elsevier BV; 2013 Oct;34(5):939–80. [Online article link]
  5. Tola EN. The effect of anesthetic agents for oocyte pick-up on in vitro fertilization outcome: A retrospective study in a tertiary center. Taiwanese Journal of Obstetrics and Gynecology. Elsevier BV; 2019 Sep;58(5):673–9. [Online article link]
  6. Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE. Human Reproduction. Oxford University Press (OUP); 2016 Jun 19;31(8):1638–52. [Online article link]
  7. Chambers GM, Paul RC, Harris K, Fitzgerald O, Boothroyd CV, Rombauts L, et al. Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success. Medical Journal of Australia. AMPCo; 2017 Jul 24;207(3):114–8. [Online article link]
  8. Humaidan P, Engmann L, Benadiva C. Luteal phase supplementation after Alaa, et al. http://doi.org/10.28969/IJEIR.v11.i2.r1 11 gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertility and Sterility. Elsevier BV; 2015 Apr;103(4):879–85. [Online article link]
  9. Van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. van der Linden M, editor. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2011 Oct 5; [Online article link]
  10. Chau LTM, Tu DK, Lehert P, Dung DV, Thanh LQ, Tuan VM. Clinical pregnancy following GnRH agonist administration in the luteal phase of fresh or frozen assisted reproductive technology (ART) cycles: Systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology: X. Elsevier BV; 2019 Jul;3:100046. [Online article link]
  11. Thomsen LH, Kesmodel US, Andersen CY, Humaidan P. Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing In Vitro Fertilization Treatment. Frontiers in Endocrinology. Frontiers Media SA; 2018 Mar 19;9. [Online article link]
  12. Fusi FM, Brigante CM, Zanga L, Mignini Renzini M, Bosisio C, Fadini R. GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial. Reproductive Biology and Endocrinology. Springer Science and Business Media LLC; 2019 Nov 29;17(1). [Online article link]
  13. Benmachiche A, Benbouhedja S, Zoghmar A, Boularak A, Humaidan P. Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial. Frontiers in Endocrinology. Frontiers Media SA; 2017 Jun 15;8. [Online article link]
  14. Ata B, Yakin K, Balaban B, Urman B. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonistprotocol: a randomized, controlled double blind study. Human Reproduction. Oxford University Alaa, et al. http://doi.org/10.28969/IJEIR.v11.i2.r1 12 Press (OUP); 2008 Mar 1;23(3):668–73. [Online article link]
  15. Yıldız GA, Şükür YE, Ateş C, Aytaç R. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. Elsevier BV; 2014 Nov;182:66–70. [Online article link]
  16. Han EJ, Kim SK, Lee JR, Jee BC, Suh CS, Kim SH. Multiple pregnancy after single or multiple embryo transfer performed according to Korean guidelines. Clinical and Experimental Reproductive Medicine. The Korean Society for Reproductive Medicine; 2015;42(4):169. [Online article link]
  17. Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the Risk of High-Order Multiple Pregnancy after Ovarian Stimulation with Gonadotropins. New England Journal of Medicine. Massachusetts Medical Society; 2000 Jul 6;343(1):2–7. [Online article link]
  18. Majumdar A, Inamdar D. Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal- phase support on IVF outcome. Journal of Human Reproductive Sciences. Medknow; 2012;5(3):279. [Online article link]
  19. Oliveira JBA, Baruffi R, Petersen CG, Mauri AL, Cavagna M, Franco JG. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reproductive Biology and Endocrinology. Springer Science and Business Media LLC; 2010 Sep 8;8(1). [Online article link]
  20. Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta- analysis. Human Reproduction Update. Oxford University Press (OUP); 2011 Jul 6;17(6):734–40. [Online article link]